Emmes

Rockville, MD, United States
Rockville, MD, United States

Time filter

Source Type

Macular edema resulting from central retinal vein occlusion is the second most common retinal vascular disease and can cause vision loss. An estimated 16 million adults worldwide are affected by retinal vein occlusion. The research was sponsored by the National Eye Institute, part of the National Institutes of Health. The Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) was presented at the Association for Research in Vision and Ophthalmology conference in Baltimore, Maryland, on May 9, 2017. According to Dr. VanVeldhuisen, this was the first large-scale study ever conducted to evaluate the comparative effectiveness of these two drugs in patients with central retinal vein occlusion. "I'd like to acknowledge the leadership of Drs. Ingrid Scott, Michael Ip and Barbara Blodi, who led the team in this important research," he said. "It's been an honor to work closely with these outstanding researchers." Dr. Anne Lindblad, president and chief executive officer of Emmes, noted, "We have a long history with the National Eye Institute and are proud of our contributions to ophthalmic research. We look forward to continuing to lead clinical trials that contribute to new, better and less expensive treatment options." About Dr. Paul VanVeldhuisen Dr. VanVeldhuisen joined The Emmes Corporation in 1993 and was Emmes' principal investigator of the Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) sponsored by the National Eye Institute. He has served as principal investigator for both government and privately funded research projects and has authored or co-authored 70 papers since he joined the company. Dr. Van Veldhuisen was named a vice president in 2006 and was promoted to the newly created position of chief operating officer last year. He received the company's Public Health Impact Award in 2013 for his team's research on the safety of cesarean sections. He holds a Ph.D. in epidemiology from The George Washington University, an M.S. in biostatistics from the University of Washington, and a B.S. in mathematics from Calvin College. About Emmes We collaborate with our clients to produce valued, trusted scientific research. Our team members at Emmes are passionate about making a difference in the quality of human health, and we have supported more than a thousand studies across a diverse range of diseases since our formation in 1977. Our research is contributing to a healthier world. For more information, visit www.emmes.com. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/emmes-recognized-in-eye-disease-research-published-by-the-journal-of-the-american-medical-association-300458651.html


News Article | June 29, 2017
Site: www.prnewswire.com

"Opening a new office during our 40th anniversary year is especially gratifying," said Dr. Anne Lindblad, president and chief executive officer of Emmes.  "Our reputation in clinical research attracts great people, and that's a key reason for our expansion." The company's decision to open an office in Frederick incorporated feedback from some employees on the length of their commute to the Rockville headquarters.  Instead of expanding office space in Rockville, the company decided to seek additional space in Frederick and offered its Rockville staff the opportunity to choose where to work. "Offering employees the choice of office location supports our priority on nurturing a family-friendly culture," added Lindblad.  She explained that company managers were proactive in communicating about the opportunity to work at either location.  The company also hosted an open house for staff and their families during Frederick office construction, and it invited a variety of local Frederick vendors, including daycare providers, to discuss their services. "We're delighted that Emmes discovered  that Frederick is a great American business destination," said Richard Griffin, Frederick's director of economic development.  "Less than an hour from Washington, we fall within the third largest biosciences cluster in the United States." He added, "We were ranked the second smartest city by Forbes.com, and we're thrilled to welcome a company like Emmes, with its roots in biostatistics and focus on scientific research, to our home." Emmes reported record revenues in 2016, and it now employs 570 Washington area employees, up from 522 a year ago.  It was ranked as the area's fifth largest bioscience employer by the Washington Business Journal in May 2017.  Last year, the company was included in the publication's largest private company list and top women-owned business list for the first time. About Emmes' Frederick Office Location:  5280 Corporate Drive, Frederick, Maryland 21703 Emmes employees working part-time or full-time in the Frederick office:  51 Emmes employees who relocated from the Rockville office: 42 Number of current Emmes Frederick job openings: 28 Emmes recruiting contact: Jennifer Hester, Vice President - Human Resources, jhester@emmes.com About Emmes We collaborate with our clients to produce valued, trusted scientific research. Our team members at Emmes are passionate about making a difference in the quality of human health, and we have supported more than a thousand studies across a diverse range of diseases since our formation in 1977.  Our research is contributing to a healthier world. For more information, visit www.emmes.com. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/emmes-opens-new-office-in-frederick-md-300481566.html


She added, "We are so proud to be recognized for listening to our employees, supporting their growth and development, and building a collaborative culture." The award was presented on June 15 at a celebration at The Washington Post's office in Washington, D.C.  Emmes and the other winners were featured in a special section of The Washington Post on Sunday, June 18. Emmes' employee relations practices were also recognized this month by the Alliance for Workplace Excellence (AWE).  The company received a 2017 Health and Wellness Seal of Approval and a Workplace Excellence Seal of Approval.  This is the third consecutive year that the company has won a Workplace Excellence Seal of Approval.  Award candidates undergo an independent evaluation of their corporate culture and management practices, family- and employee-friendly programs, health and wellness initiatives, growth and learning opportunities, and a variety of other employee relations criteria.  The award was presented on June 9 at the organization's awards luncheon at the Gaithersburg Marriott Washingtonian Center. About Emmes We collaborate with our clients to produce valued, trusted scientific research. Our team members at Emmes are passionate about making a difference in the quality of human health, and we have supported more than a thousand studies across a diverse range of diseases since our formation in 1977.  Our research is contributing to a healthier world. For more information, visit our website at www.emmes.com. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/emmes-ranked-as-a-top-area-workplace-for-second-consecutive-year-by-the-washington-post-300480179.html


News Article | July 12, 2017
Site: www.prnewswire.com

More than 50 Emmes employees opted to work full- or part-time in the Frederick office.  The company, which has been ranked as the area's fifth largest bioscience employer, is now recruiting to fill 28 positions in anticipation of additional growth at this location. The Maryland Department of Commerce was one key player in assisting the company's expansion into Frederick County, and Emmes is now eligible for the state's Job Creation Tax Credit. "I'm excited to see one of the largest bioscience employers in the region expand and add new jobs in Maryland," said Maryland Commerce Secretary Mike Gill. "The Emmes Corporation celebrates its 40th anniversary this year, and this is an excellent way to celebrate its growth and investment in our life sciences community and in Frederick and Montgomery counties." Frederick County Executive Jan Gardner, a speaker at the company's ribbon-cutting event, noted, "Emmes is a perfect fit for Frederick County.  It's a great place to do business and home to more than 80 companies that conduct cutting-edge research or manufacture biologic products. Using our 'fast track' process gave the company the necessary permits to start the build-out of the office space in only six days." Helen Propheter, director of the Frederick County Office of Economic Development, added, "Our Office of Economic Development was thrilled to be able to fast track the permits, assist in planning a Quality of Life Career Fair, and support the office opening ceremony.  Our goal was to help the company make a smooth transition." Joining Emmes executives and Frederick-based employees at the ribbon-cutting event were representatives from the Maryland Department of Commerce, Frederick County Office of Economic Development, Frederick County Workforce Services, Visit Frederick and Downtown Frederick.  Emmes partners and other supporters also attended. About Emmes We collaborate with our clients to produce valued, trusted scientific research. Our team members at Emmes are passionate about making a difference in the quality of human health, and we have supported more than a thousand studies across a diverse range of diseases since our formation in 1977.  Our research is contributing to a healthier world. For more information, visit www.emmes.com.


Emmes, together with Vanderbilt University, used a "systems biology" approach that examined changes in both gene and protein expression in several human immune cell types simultaneously over time.  The research was funded by the National Institute of Allergy and Infectious Diseases, which is part of the National Institutes of Health. Ultimately, the results from these types of system biology studies will help develop better and more personalized vaccines and result in a greater understanding of how the human immune system responds to vaccines, adjuvants and infectious agents. The overall goal of this study was to better understand how the adjuvant AS03 enhanced H5N1 avian flu vaccine by integrating multiple genomics and proteomics ("-Omics") technologies. The Proteomics paper, which addressed the results from the protein analysis, followed earlier research that summarized gene expression findings. According to Dr. Anne Lindblad, president and chief executive officer of Emmes, "These efforts continue to strengthen our bioinformatics portfolio.  We've invested in our infrastructure to support reproducible and scalable bioinformatics research, and we hope further research will result in better, more personalized vaccines." Other Emmes systems biology efforts involve clinical trials to assess -Omics responses to vaccines addressing a different form of avian flu (H7N9), as well as filovirus and yellow fever vaccines. About the Research Fatality rates for H5N1 avian flu have been as high as 80%, yet vaccines developed following the same procedures as seasonal flu are not very effective when given alone.  Several studies have found that adjuvants, chemicals that stimulate the immune response, can increase the effectiveness of H5N1 avian flu vaccines.  How adjuvants do this is not well understood. The research addressed whether large scale systems biology approach generating over two terabytes of raw data describing temporal changes in thousands of white blood cell molecules from 20 vaccinated individuals (half with AS03 adjuvant) could provide the answer. The previously conducted transcriptomics research had revealed strong AS03-specific stimulation of gene expression responses in three types of white blood cells, neutrophils, monocytes and dendritic cells, 24 hours following vaccination. Some of these responses were correlated with later generation of protective levels of antibodies. The most recent proteomic analysis confirmed that in the group that received the adjuvant, there was an increase in a particular biological function of white blood cells referred to as "antigen processing and presentation." This event occurs when white blood cells digest and process a foreign invader to enhance the immune response against it.  This proteomic finding was noted to occur two days after the corresponding transcriptomic signal. Together these analyses provided evidence that AS03 administered with H5N1 avian flu vaccine stimulated subsets of white blood cells to increase expression of genes and proteins that improve uptake and processing of antigens. In addition to this key finding, the results provided details about the timing and composition of several other important immune system-related processes that were activated in response to AS03 and how the activation differed between immune cell types. Emmes served as the Statistical and Data Coordinating Center for this research, with Heather Hill serving as project manager.  The analysis of the multi-terabyte dataset was devised and carried out by the Emmes bioinformatics team, led by Johannes Goll who was co-lead author on both publications.  The bioinformatics team used scalable cloud resources to store, analyze and integrate the vast amounts of -Omics data required for the study. This study was conducted by the Vaccine and Treatment Evaluation Unit at Vanderbilt University (Contract HHSN272200800007C), with data analysis performed by the Statistical and Data Coordinating Center for Clinical Research in Infectious Diseases at The Emmes Corporation (Contract HHSN272201500002C).  Both contracts are supported by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. About Emmes We collaborate with our clients to produce valued, trusted scientific research. Our team members at Emmes are passionate about making a difference in the quality of human health, and we have supported more than a thousand studies across a diverse range of diseases since our formation in 1977.  Our research is contributing to a healthier world. For more information, visit www.emmes.com.


News Article | August 8, 2017
Site: www.marketwired.com

Urban Migration Continues as Downtown Becomes Hot Spot for Commerce & Culture SAN DIEGO, CA--(Marketwired - August 08, 2017) - In following the current trends in corporate urban migration, two leading global firms have signed leases with EMMES Realty Services of California LLC and will be relocating to 1 Columbia Place in downtown San Diego. Global digital marketing agency iProspect, which has more than 4,200 employees in 91 offices across 55 countries, now occupies an entire floor of 1 Columbia Place. The company, which has relocated its 80 local employees from UTC to downtown, works with leading brands such as General Motors, Adidas, T-Mobile, Hilton, Sunglass Hut, and Microsoft. "We're so excited to now be in the center of San Diego, and our employees look forward to using all the amenities that 1 Columbia Place and downtown offer," said Jon Leicht, SVP Managing Director, West, iProspect. 1 Columbia Place includes superior technology infrastructure such as enhanced Wi-Fi coupled with a building-wide Fiber Optic Network, as well as amenities such as expansive terraces with hotel-style lounge seating, in-building retail shops and restaurants, banking, multiple conference centers, an indoor cycling studio, secure tenant bike storage, as well as shower and locker facilities. The 27-story, Class A building is an iconic landmark noted for its distinctive glass façade, stair-step design and high-flying American flag, one of the largest in downtown San Diego, residing on its rooftop. The building also features a dramatic seven-story atrium lobby, common and private exterior terraces, and spectacular views of San Diego Bay, Coronado Island, Balboa Park and all of downtown San Diego. The amenities offered at 1 Columbia Place and downtown played a part in the decision by global engineering consulting firm Syska Hennessy Group to move from its Kearny Mesa office. Sean Marcel, associate partner of Syska's San Diego office, said downtown also puts the company closer to clients, colleagues, restaurants, and employee residences. In fact, he said, some of the company's 27 employees plan to bike to work. "Moving downtown puts us close to a large portion of our clients," Marcel said. "After settling on the downtown area, we looked at about 25 places -- the Columbia District, Little Italy, Gaslamp, and East Village. Our team is psyched about our new space with the views and amenities to support a collaborative environment." "Our New York office is right in Times Square, so I'm used to just walking downstairs to meet with clients throughout Midtown," he added. "As a professional service firm, being able to easily meet a client for lunch or coffee really helps us to support their projects and build relationships." Syska provides MEP, technology, commissioning and architectural lighting design to the aviation, biotechnology, convention centers, corporate offices, healthcare, higher education and hospitality sectors. The firm's local work has been included in the Manchester Grand Hyatt San Diego and the iconic County Administration Center, in Terminals 1 and 2 at the San Diego International Airport, and on the campuses of University of California, San Diego and San Diego State University. "We are pleased to welcome Syska Hennessy and iProspect as new tenants within the downtown San Diego EMMES portfolio," said Mark Kuske, Asset Manager of EMMES Reality Services of California LLC. "As downtown San Diego grows its reputation as a catalyst for innovation, creativity, and entrepreneurialism, we are seeing more and more companies choosing to be downtown instead of the suburbs. We think this trend will continue and hope to attract more businesses downtown by activating the street fronts along Columbia Street, as well as revamping our downtown properties to revitalize San Diego's urban landscape, and transform downtown into a true cutting-edge urban center." EMMES Realty Services of California LLC is a member of The EMMES Group of Companies. Founded in 1992, with offices in New York and California, The EMMES Group of Companies and its affiliates are engaged in principal real estate investments, funds management and real estate services. The downtown San Diego EMMES portfolio is comprised of four high-rise office properties: 1 Columbia Place, 2 Columbia Place, 701 B Street, and 707 Broadway, along with a large parking and retail facility, which was recently rebranded to 6th & A Parking. For more information, visit www.emmesco.com. Image Available: http://www.marketwire.com/library/MwGo/2017/8/7/11G143805/Images/EMMESiProspect1-d52e85e249198829b071ec639538d443.jpg Image Available: http://www.marketwire.com/library/MwGo/2017/8/7/11G143805/Images/EMMESiProspect2-1886937decde8ffb9015fdbe65bf9e6e.jpg Image Available: http://www.marketwire.com/library/MwGo/2017/8/7/11G143805/Images/EMMESSyska_Hennessy1-4812883ef8969793b0a916b7dab02c7c.jpg Image Available: http://www.marketwire.com/library/MwGo/2017/8/7/11G143805/Images/EMMESSyskaHennessy2-571ed62d6bcd91dfb96dbc56b72d73a0.jpg


News Article | August 2, 2017
Site: www.prnewswire.com

The company's role as the data coordinating center involves study design, data management, regulatory support, pharmacovigilance, site monitoring, and statistical analyses. "This is one of Emmes' largest contracts," noted Dr. Anne Lindblad, president and chief executive officer.  "More importantly, it reflects the government's confidence in our ability to support both NIH and the Food and Drug Administration in a broad mandate to protect the nation's children by ensuring that the medicines are safe, effective and used in the proper doses." The Best Pharmaceuticals for Children Act was enacted in 2002 and subsequently reauthorized by the Food and Drug Administration (FDA) in 2007 and 2012. One of its goals involves conducting clinical trials and research for on- and off-patent drug products meriting further study for children.   NICHD activities are aimed at improving pediatric drug therapies through preclinical and clinical testing that lead to drug labeling change. Most new drugs that have potential applications in pediatric care must be tested in children prior to receiving marketing approval in the U.S.  However, the majority of previously approved drug therapies have not been labeled specifically for children and are used off-label without adequate studies in children. "This contract represents an ongoing, successful collaboration between NIH and the FDA," said Lindblad.  "Emmes' long history in serving both agencies is especially useful, given the broad mission of updating drug labels appropriately to address the needs of children." She continued, "What is especially noteworthy about this project is that it does not target one specific disease but a wide population – infants, young children and teenagers.  We're proud to help bring accurate drug labeling to inform physicians, parents and caregivers." Emmes held the data coordinating center role in the previous contract with the NICHD, which ran from 2009 to mid-2017. We collaborate with our clients to produce valued, trusted scientific research. Our team members at Emmes are passionate about making a difference in the quality of human health, and we have supported more than a thousand studies across a diverse range of diseases since our formation in 1977.  Our research is contributing to a healthier world. For more information, visit the Emmes website at www.emmes.com.


Meador K.J.,Emory University | Baker G.A.,University of Liverpool | Browning N.,EMMES | Cohen M.J.,University of Georgia | And 8 more authors.
The Lancet Neurology | Year: 2013

Background: Many women of childbearing potential take antiepileptic drugs, but the cognitive effects of fetal exposure are uncertain. We aimed to assess effects of commonly used antiepileptic drugs on cognitive outcomes in children up to 6 years of age. Methods: In this prospective, observational, assessor-masked, multicentre study, we enrolled pregnant women with epilepsy on antiepileptic drug monotherapy (carbamazepine, lamotrigine, phenytoin, or valproate) between October, 1999, and February, 2004, at 25 epilepsy centres in the UK and the USA. Our primary outcome was intelligence quotient (IQ) at 6 years of age (age-6 IQ) in all children, assessed with linear regression adjusted for maternal IQ, antiepileptic drug type, standardised dose, gestational birth age, and use of periconceptional folate. We also assessed multiple cognitive domains and compared findings with outcomes at younger ages. This study is registered with ClinicalTrials.gov, number NCT00021866. Findings: We included 305 mothers and 311 children (six twin pairs) in the primary analysis. 224 children completed 6 years of follow-up (6-year-completer sample). Multivariate analysis of all children showed that age-6 IQ was lower after exposure to valproate (mean 97, 95% CI 94-101) than to carbamazepine (105, 102-108; p=0·0015), lamotrigine (108, 105-110; p=0·0003), or phenytoin (108, 104-112; p=0·0006). Children exposed to valproate did poorly on measures of verbal and memory abilities compared with those exposed to the other antiepileptic drugs and on non-verbal and executive functions compared with lamotrigine (but not carbamazepine or phenytoin). High doses of valproate were negatively associated with IQ ( r=-0·56, p<0·0001), verbal ability ( r=-0·40, p=0·0045), non-verbal ability ( r=-0·42, p=0·0028), memory ( r=-0·30, p=0·0434), and executive function ( r=-0·42, p=0·0004), but other antiepileptic drugs were not. Age-6 IQ correlated with IQs at younger ages, and IQ improved with age for infants exposed to any antiepileptic drug. Compared with a normative sample (173 [93%] of 187 children), right-handedness was less frequent in children in our study overall (185 [86%] of 215; p=0·0404) and in the lamotrigine (59 [83%] of 71; p=0·0287) and valproate (38 [79%] of 40; p=0·0089) groups. Verbal abilities were worse than non-verbal abilities in children in our study overall and in the lamotrigine and valproate groups. Mean IQs were higher in children exposed to periconceptional folate (108, 95% CI 106-111) than they were in unexposed children (101, 98-104; p=0·0009). Interpretation: Fetal valproate exposure has dose-dependent associations with reduced cognitive abilities across a range of domains at 6 years of age. Reduced right-handedness and verbal ( vs non-verbal) abilities might be attributable to changes in cerebral lateralisation induced by exposure to antiepileptic drugs. The positive association of periconceptional folate with IQ is consistent with other recent studies. Funding: US National Institutes of Health, UK Epilepsy Research Foundation. © 2013 Elsevier Ltd.


News Article | November 17, 2016
Site: www.marketwired.com

SAN DIEGO, CA--(Marketwired - November 17, 2016) - EMMES Realty Services of California LLC announced a multiple floor lease today with a high-tech tenant who will be relocating and expanding to its 1 Columbia Place property in downtown San Diego. The tenant, highly respected video game development studio Psyonix, will be expanding within the downtown EMMES portfolio from a 9,000 square-foot office space at 707 Broadway to a 40,000 square-foot office at 1 Columbia Place. Psyonix, which was represented by Jordan Williams of Strom Commercial for its new lease, will occupy two contiguous floors in the high-rise section of the 27-story building. Psyonix's expansion highlights both the flexibility within the downtown EMMES portfolio to accommodate significant tenant growth and downtown San Diego's continued attractiveness to growing, innovative companies, which are capitalizing on the area's rich amenity base and deep talent pool. "We are thrilled for Psyonix's success and for its continued growth within the downtown EMMES portfolio," said Jordan Johnson, vice president of EMMES Realty Services of California LLC. "Downtown San Diego has arrived as a dynamic hub for innovation-oriented companies and EMMES is working hard to design, upgrade and improve our buildings to fit today's innovation companies' cultures and needs." Johnson added that this includes superior technology infrastructure such as enhanced Wi-Fi coupled with a Building-Wide Fiber Optic Network, as well as amenities such as expansive terraces with hotel-style lounge seating, in-building retail shops and restaurants, banking, multiple state-of-the-art building conference/meeting rooms, an indoor cycling studio, secure tenant bike storage, as well as shower and locker facilities. Psyonix -- best known for the commercial success of its video game, Rocket League®, which has sold more than 8 million copies to date -- relocated from North Carolina to San Diego in 2009 and has grown exponentially ever since. "We have experienced tremendous growth since the launch of Rocket League® in July of 2015. The game's huge success with more than 22 million players is a big reason why we're moving into the new office space," said Dave Hagewood, Psyonix founder, CEO and studio director. "We needed a fantastic modern location like 1 Columbia Place that could better accommodate our increasing team size and loftier goals." Hagewood added that the game studio's prime location downtown will also attract more creative talent to Psyonix. "The spectacular views, proximity to quality restaurants, and beautiful architecture at 1 Columbia Place are all amazing values for us," Hagewood said. "San Diego is also an excellent alternative to other large cities in general because of its close proximity to great beaches and family entertainment. There's definitely a beach vibe all over town, which is perfect for our company culture and mindset." EMMES Realty Services of California LLC is a member of The EMMES Group of Companies. Founded in 1992, with offices in New York and California, The EMMES Group of Companies and its affiliates are engaged in principal real estate investments, funds management and real estate services. The downtown San Diego EMMES portfolio is comprised of four high-rise office properties: 1 Columbia Place, 2 Columbia Place, 701 B Street, and 707 Broadway, along with a large parking and retail facility, which was recently rebranded to 6th & A Parking. For more information, visit www.emmesco.com. Based in San Diego, CA, Psyonix is a critically-acclaimed independent video game developer and leading expert in Unreal Engine technology. For more than a decade, the studio has been a driving force behind some of the most successful games in the industry, including Gears of War, Mass Effect 3, XCOM: Enemy Unknown, Bulletstorm, Unreal Tournament III, Unreal Tournament 2004, and the award-winning Sports-Action hit, Rocket League®. For more information, visit www.psyonix.com.


ROCKVILLE, Md., Nov. 14, 2016 /PRNewswire-USNewswire/ -- The Emmes Corporation today announced that a large team of scientists and health professionals including those from the company, LDS Hospital in Salt Lake City, Utah, Lovelace Biomedical Environmental Research Institute in...

Loading Emmes collaborators
Loading Emmes collaborators